AI-powered
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease An Exploratory Model
Study on Bone Health in Multiple Myeloma Patients
Recruiting
18 years - 65 years
Male
Phase
2
1 Location
Brief description of study.
The purpose of this research is to learn if substances that cause bone destruction are increased in multiple myeloma patient's blood or bone marrow.
Detailed description of study
The purpose of this research is to learn if substances that cause bone destruction are increased in multiple myeloma patient's blood or bone marrow.
Participants may be paid for their participation.
Participants may be paid for their participation.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Myeloma Bone Disease,Multiple Myeloma,Myeloma,Cancer,Oncology
-
Age: 18 years - 65 years
-
Gender: Male
Inclusion Criteria
Diagnosed with multiple myeloma
Diagnosed with multiple myeloma
Normal
0
false
false
false
EN-US
X-NONE
X-NONE
Exclusion Criteria
Currently pregnant or breastfeeding
Have a history of bleeding conditions
Exclusion Criteria
Currently pregnant or breastfeeding
Have a history of bleeding conditions
Updated on
19 Feb 2024.
Study ID: 1203008199 (IUCRO-0381)
This study investigates whether substances that lead to bone destruction are present in higher amounts in the blood or bone marrow of patients with multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells, a kind of white blood cell found in bone marrow.
Participants in this study will have their blood or bone marrow tested to measure the levels of these substances. This involves collecting samples to analyze the presence of bone destructive substances.
- Who can participate: Adults with multiple myeloma can join. Participants should not be pregnant, breastfeeding, or have bleeding conditions.
- Study details: Participants will have blood or bone marrow tests to measure certain substances.